Results 91 to 100 of about 1,460,729 (292)

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

Prostate Cancer, 2011
Introduction. Concern regarding overtreatment of prostate cancer (CaP) is leading to increased attention on active surveillance (AS). This study examined CaP survivors on AS and compared secondary treatment patterns and overall survival by race/ethnicity.
Jennifer Cullen, Stephen A. Brassell, Yongmei Chen, Christopher Porter, James L'Esperance, Timothy Brand, David G. McLeod   +6 more
doaj   +1 more source

Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. [PDF]

, 2015
Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy.
Bouvet, Michael, Hoffman, Robert M, Hu, Cameron, Matsumoto, Yasunori, Miwa, Shinji, Nakanishi, Hayao, Toneri, Makoto, Yano, Shuya, Zhang, Yong, Zhao, Ming   +9 more
core   +3 more sources

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)

Breast Cancer Research
Up to 40% of patients with estrogen receptor (ER)-positive breast cancer will develop resistance against the majority of current ER-directed therapies.
Jane Foo, Francesco Gentile, Shabnam Massah, Helene Morin, Kriti Singh, Joseph Lee, Jason Smith, Fuqiang Ban, Eric LeBlanc, Robert Young, Natalie Strynadka, Nada Lallous, Artem Cherkasov   +12 more
doaj   +1 more source

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2018
Prostate cancer often develops resistance to androgen receptor (AR) targeting drugs. Here, the authors show that, under conditions of hypoxia, AR inhibition via enzalutamide increases the expression of the glycolytic enzyme phosphoglucose isomerase (GPI)
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

Molecular Oncology, EarlyView.
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié, Umberto Malapelle, Catherine Alix‐Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet‐Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman   +13 more
wiley   +1 more source

Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model [PDF]

, 2016
INTRODUCTION. Decreased expression of highly immunogenic cancer-testis antigens (CTA) might help tumor to achieve low immunogenicity, escape immune surveillance and grow unimpeded. Our aim was to evaluate CTA expression in tumor and normal tissues and to
Goliadze, Ekaterine, Guruli, Georgi, Manjili, Masoud H., Petrossian, Albert A., Robinson, Samuel P., Sulek, Jay E., Toor, Amir, Zhou, Shaoqing   +7 more
core   +2 more sources

PARP inhibitors in prostate cancer: time to narrow patient selection? [PDF]

, 2020
Mark C. Markowski, Emmanuel S. Antonarakis   +1 more
openalex   +1 more source

Prostate cancer disparities among American Indians and Alaskan Natives in the United States [PDF]

, 2023
Carissa Chu, Michael Leapman, Shoujun Zhao, Janet E. Cowan, Samuel L. Washington, Matthew R. Cooperberg   +5 more
openalex   +1 more source